Analytical Quality by Design (AQbD): A Contemporary Framework for Pharmaceutical Analytical Development.

The pharmaceutical sector is governed by exacting regulatory expectations, all oriented toward guaranteeing that medicines consistently embody the required levels of quality, safety, and therapeutic efficacy. Analytical testing underpins these assurances, serving as the essential mechanism through which the identity, purity, potency, and overall quality of both drug substances and finished products are assessed across the product lifecycle. For much of the field's history, method development was guided by empirical, incremental strategies most notably the one-factor-at-a-time (OFAT) paradigm, in which individual variables are adjusted sequentially while others remain constant. Although such approaches may deliver functionally acceptable results, they provide only a shallow understanding of how variables interact, and they are prone to generating methods that lack robustness, suffer from variability, and encounter resistance during regulatory scrutiny [13,16].

The concept of Quality by Design (QbD) was introduced by regulatory bodies to transcend these limitations, articulated most prominently through ICH guidelines Q8, Q9, Q10, and Q11. QbD repositions quality as a designed attribute rather than an inspected one, prioritizing scientific understanding of the process, predefined product objectives, and structured risk management rather than reliance on end-stage

testing. The widespread uptake of QbD across pharmaceutical manufacturing and formulation science has catalysed a paradigm shift, enabling more profound process comprehension, greater development efficiency, and enhanced regulatory flexibility [1–4,10].

Inspired by the achievements of QbD in production and formulation settings, its core tenets have been translated to the domain of analytical science through AQbD. This integrated, lifecycle-oriented framework guarantees that analytical methods are purpose-fit from conception through to routine deployment and eventual retirement. The cornerstone of AQbD is the ATP, which codifies the target performance requirements that the method must achieve. Subsequent identification of Critical Quality Attributes (CQAs) or Critical Analytical Procedure Attributes (CAPAs) alongside Critical Method Parameters (CMPs/CAPPs) is accomplished through structured risk evaluation [13,14,18].

Risk management within AQbD, guided by ICH Q9, is operationalized through tools such as Ishikawa fishbone diagrams, FMEA, and risk ranking frameworks. These instruments clarify the causal web connecting method variables to performance outcomes, enabling practitioners to direct their experimental attention toward the factors that most significantly influence method quality. Subsequently, DoE provides a multivariate statistical lens through which variable interactions are examined, conditions are refined, and method robustness is established [2,13,16].

Among the most significant outputs of AQbD-based development is the MODR a multi-dimensional parameter envelope within which the method reliably delivers acceptable performance. Unlike methods governed by single fixed operating points, the MODR enables parametric adjustments without triggering revalidation obligations, thereby accommodating ongoing refinement and supporting lifecycle management as endorsed by USP General Chapter <1220> and ICH Q14 [5,7,18].

Liquid, gas, and related chromatographic techniques constitute the workhorses of pharmaceutical analysis. Their inherent multi-parameter complexity makes them particularly receptive to AQbD-guided optimization, and published literature consistently demonstrates that AQbD-developed chromatographic methods exhibit superior robustness and regulatory compliance relative to conventionally developed counterparts [13,16,18].

AQbD has also attracted growing interest from the herbal and natural product analysis community. Botanical systems present a formidable combination of chemical complexity, compositional variability, and sensitivity to pre-analytical factors such as geographical provenance, harvesting practices, and extraction conditions all of which can materially affect quality. AQbD furnishes a structured methodology to manage this variability, select appropriate analytical targets, and build dependable quality control frameworks [14,31].

The progressive globalization of pharmaceutical development has placed greater weight on harmonized regulatory standards. ICH, founded in 1990, has been instrumental in aligning technical requirements across jurisdictions, reducing redundant regulatory submissions, and fostering efficient drug development workflows. The embedding of AQbD within ICH's broader regulatory architecture reflects a broader transition toward lifecycle thinking, evidence-based decision-making, and continuous analytical improvement [1–5].

The application of AQbD is not without its difficulties. The methodology demands statistical proficiency, careful documentation, and sometimes considerable upfront resource investment. Notwithstanding these demands, its capacity to augment method robustness, suppress OOS rates, and provide regulatory latitude has made it a progressively standard expectation within modern pharmaceutical analytical laboratories [13,14,18].

Fig. 1 Analytical quality by design

This review aims to deliver a thorough and integrated account of AQbD, examining its conceptual underpinnings, operational tools, regulatory dimensions, and real-world applications particularly in chromatographic analysis and the analysis of botanically complex matrices. Special attention is devoted to risk management strategies and lifecycle governance as enablers of effective AQbD adoption across both industrial and academic contexts.

2. PRINCIPLES OF ANALYTICAL QUALITY BY DESIGN

At its core, AQbD is a proactive, knowledge-driven paradigm for analytical method development, one that prioritizes method understanding, anticipated performance, and regulatory foresight over reactive troubleshooting. By embedding quality assurance into the very architecture of method development, AQbD stands in contrast to traditional frameworks that treat validation as a terminal checkpoint. Regulatory guidance including ICH Q8, Q9, Q10, and Q14 collectively articulate the scientific and organizational principles that animate AQbD in pharmaceutical settings [1–6].

2.1 Analytical Target Profile (ATP)

The ATP functions as the guiding document for the entire method development endeavour. It crystallizes the intended use of the analytical procedure and defines performance requirements across dimensions including accuracy, precision, specificity, detection capability, and working concentration range. Every subsequent development decision is referenced against the ATP, ensuring that method design remains goal-directed [7].

2.2 Critical Quality Attributes (CQAs)

CQAs are those measurable chromatographic or spectroscopic properties for example, peak resolution, retention behaviour, asymmetry factor, and detection sensitivity  that directly determine whether a method fulfils its ATP criteria. Identifying CQAs focuses the development effort on the performance attributes that genuinely matter [8].

2.3 Risk Assessment and Risk Management

Structured risk appraisal uses tools including Ishikawa diagrams, FMEA, and Pareto charts to reveal the sources of analytical variability and quantify the potential impact of individual parameters. This step ensures that subsequent experimental resources are invested where they will have the greatest influence on method performance [9].

2.4 Critical Method Parameters (CMPs)

CMPs encompass the operational variables such as mobile phase composition, eluent flow rate, column thermostatting temperature, and pH whose controlled variation demonstrably affects analytical outcomes. Proper identification and management of CMPs is central to establishing a robust method [10].

2.5 Design of Experiments (DoE)

Rather than modifying one factor at a time, DoE investigates multiple variables in a coordinated fashion, revealing interaction effects and enabling statistically grounded optimization. Designs including factorial arrays, central composite designs, and Box–Behnken matrices are employed depending on the number of factors and the nature of the response surface [11].

2.6 Method Operable Design Region (MODR)

The MODR defines the multidimensional parameter space within which all ATP criteria are consistently satisfied. It provides a mechanistic basis for post-approval parameter adjustments, supporting both regulatory flexibility and continuous improvement without necessitating fresh validation exercises [12].

2.7 Control Strategy

Control strategies encompass the procedural and instrumental safeguards such as system suitability protocols and routine parameter monitoring that ensure method performance remains stable during day-to-day analytical operations [13].

2.8 Method Validation

Validation formally confirms that the method meets its ATP-defined performance criteria. Conducted in accordance with ICH Q2 guidance, validation activities address accuracy, precision, specificity, and robustness, among other attributes [14].

2.9 Lifecycle Management

AQbD conceives of analytical methods as living entities requiring ongoing stewardship. Continuous performance monitoring, transfer activities between laboratories, and periodic reassessment collectively constitute the lifecycle management function that sustains long-term analytical integrity [15].

3. CONCEPT OF ANALYTICAL QUALITY BY DESIGN

AQbD extends the QbD philosophy first articulated for pharmaceutical manufacturing in ICH Q8(R2) into the domain of analytical chemistry, replacing ad hoc, empirically driven workflows with a structured, understanding-based development model [1,10]. The central ambition is to cultivate a deep mechanistic appreciation of how method variables collectively govern performance, rather than simply tuning individual parameters until outcomes appear acceptable [13,14].Development begins with the ATP, from which performance requirements including accuracy, precision, specificity, and sensitivity are drawn. This profile governs all subsequent design decisions and serves as the benchmark against which the final method is assessed [6,13].Once the ATP is established, CQAs/CAPAs and CMPs are uncovered through systematic risk evaluation. Ishikawa diagrams and FMEA are commonly deployed at this stage to visualize cause-and-effect relationships and rank the relative importance of individual variables [2,14]. DoE is subsequently employed to explore variable interactions and identify optimum operating conditions within a principled experimental framework [16].The net result is an MODR a defined parameter window guaranteeing reliable, ATP-compliant performance  accompanied by a control strategy and lifecycle management plan that maintain analytical capability over the long term [6,8]. In aggregate, AQbD delivers methods that are markedly more robust, less prone to variability, and better positioned to satisfy evolving regulatory expectations throughout the pharmaceutical product lifecycle.

4. RISK ASSESSMENT IN AQBD

Risk assessment occupies a pivotal position within AQbD, supplying the evidential basis for directing experimental resources toward the variables most capable of undermining method performance. Its application is mandated by ICH Q8(R2), Q9, and Q14, all of which stipulate that scientific understanding and quality risk management must inform analytical development [1,2,5].

Following ATP definition, each potential variable is classified as a CQA, CAPA, or CMP and subjected to a quality risk management evaluation that scores the probability, severity, and detectability of associated failure modes. This generates a prioritized risk hierarchy that directs subsequent experimental attention [13,14].

The principal instruments used in risk assessment include Ishikawa diagrams for mapping causal relationships, FMEA for computing Risk Priority Numbers (RPNs) from severity, occurrence, and detectability scores, and Risk Ranking and Filtering (RRF) for comparing variables by their aggregate impact on method performance [13,14,16].Risk assessment outcomes feed directly into the MODR development process by flagging parameters requiring experimental investigation, and ultimately into the control strategy, which specifies the monitoring and management actions that keep identified risks in check. Through this continual risk governance, AQbD substantially reduces analytical variability and strengthens the entire lifecycle management framework.

5. DESIGN OF EXPERIMENTS (DOE) IN AQBD

Design of Experiments is a multivariate statistical methodology that occupies a central position in AQbD, enabling the simultaneous investigation of multiple analytical variables and their interactions. This stands in direct contrast to OFAT approaches, which are incapable of revealing synergistic or antagonistic effects between factors. By capturing the full complexity of the analytical system within a structured experimental framework, DoE accelerates development, reduces costs, and underpins the robust, lifecycle-oriented methods that AQbD demands. Its application is consistent with the scientific and risk-management principles of ICH Q8(R2), Q9, and Q14 [1,2,5].

In the AQbD workflow, DoE is initiated after ATP definition and risk assessment have been completed. The ATP supplies performance benchmarks; risk assessment identifies the CMPs and CQAs that deserve experimental attention. These prioritized factors become the independent variables in the DoE study, and their effects on defined analytical responses are systematically characterized [13,14].

5.1 Steps in DoE Implementation

Step 1: Defining Experimental Objectives

Each DoE exercise begins with a clear statement of intent  whether the purpose is method optimization, robustness evaluation, variable screening, or MODR delineation. Unambiguous objectives guide design selection and response measurement.

Step 2: Selection of Critical Factors

Variables identified through risk assessment are nominated for systematic investigation. In chromatographic applications, these typically include mobile phase composition, eluent flow rate, column temperature, buffer pH, detection wavelength, injection volume, and sample preparation parameters all of which are known to influence resolution, peak shape, retention time, and analytical sensitivity.

Step 3: Experimental Design Selection

Screening designs including full and fractional factorial arrays and Plackett–Burman matrices are employed when the goal is to determine which among many candidate factors are statistically significant. Once important factors are established, optimization designs such as Central Composite Design (CCD), Box–Behnken Design (BBD), and Response Surface Methodology (RSM) are applied to map the response surface and identify operating optima [16].

Step 4: Experimental Execution

Experiments are run in accordance with the randomized design matrix. Chromatographic responses  including resolution, retention time, peak symmetry, signal-to-noise ratio, and sensitivity  are recorded precisely for each experimental run.

Step 5: Statistical Analysis

Analysis of Variance (ANOVA) is performed using dedicated software to identify statistically significant effects and interactions. Regression models relating independent variables to analytical responses are constructed, and residual diagnostics confirm model validity [16].

Step 6: Optimization and MODR Establishment

Response surface plots and overlay contour graphs visually communicate how analytical responses vary across the factor space. These representations identify regions of simultaneous compliance with all ATP criteria, defining the MODR [13].

5.2 Advantages of DoE

Deployment of DoE within the AQbD framework delivers a range of tangible advantages: simultaneous factor evaluation, explicit characterization of interaction effects, improved method robustness, compressed development timelines, lower experimental cost, deeper mechanistic understanding, regulatory flexibility arising from the MODR, and a structured foundation for lifecycle monitoring. The knowledge generated also informs the control strategy and continued performance verification activities endorsed by USP <1220> and ICH Q14 [5,7].

5.3 Chromatographic Applications of DoE

In HPLC, UPLC, and GC development, DoE streamlines optimization of mobile phase composition, gradient profiles, stationary phase selection, buffer concentration, and temperature settings. These structured investigations consistently improve resolution, shorten analysis times, and strengthen method reproducibility. Additionally, by identifying robust operating windows, DoE measurably reduces OOS incidence during routine analytical use [13,16].

5.4 Implementation Challenges

Despite its clear benefits, DoE adoption can be impeded by the need for statistical competency, access to specialized software, elevated upfront planning demands, and requirements for cross-disciplinary cooperation. Nevertheless, the longer-term returns in method reliability, diminished regulatory risk, and superior lifecycle management capacity consistently justify the initial investment [14].

Taken together, DoE functions as a methodological cornerstone of AQbD, unifying risk assessment, statistical modelling, and lifecycle governance within a single coherent analytical development framework.

6. Method Operable Design Region (MODR)

The MODR represents one of the most consequential deliverables of the AQbD process. Defined as the multidimensional parameter space within which an analytical method consistently satisfies its ATP criteria, the MODR operationalizes the design space concept from ICH Q8(R2), Q9, and Q14 within the analytical context, establishing a tangible basis for both operational flexibility and regulatory confidence [1,2,5].

MODR development proceeds from ATP definition and CQA/CMP identification through risk assessment and DoE. Statistical modelling of DoE results reveals the functional relationships between CMPs and analytical responses, and regions of the parameter space that satisfy all performance criteria simultaneously are formally demarcated as the MODR [13,14].

A particularly important regulatory advantage of the MODR lies in its enabling of parameter adjustments without revalidation, provided that the revised operating point remains within the established region and ATP criteria are maintained. This feature directly supports the lifecycle management and continuous improvement philosophies central to ICH Q14 and USP <1220> [5,7].

6.1 MODR DEVELOPMENT SEQUENCE

Define the ATP

Performance criteria including accuracy, precision, resolution, sensitivity, and specificity are documented. These specifications set the outer boundaries that the MODR must satisfy.

Identify CMPs via Risk Assessment

Ishikawa diagrams, FMEA, and risk ranking methods are deployed to isolate the operational variables  mobile phase composition, flow rate, column temperature, buffer pH, detection wavelength that most significantly influence analytical outcomes [2,14].

Execute DoE

Systematic variation of CMPs across defined experimental ranges, with measurement of analytical responses, generates the dataset from which response surface models are constructed. These models express each CQA as a function of the CMPs under investigation [16].

Establish the MODR

Response surface plots, contour maps, and overlay diagrams identify the region where all ATP criteria are simultaneously satisfied. This region constitutes the MODR [13].

6.2 Graphical Representation

MODR boundaries are typically visualized using contour plots, three-dimensional response surface renderings, and overlay plots that superimpose the acceptable regions for each CQA. These tools facilitate selection of an optimal working point within the MODR.

6.3 Advantages of the MODR Concept

Establishing an MODR conveys numerous practical benefits: enhanced method robustness, reduced OOS rates, greater regulatory latitude, diminished revalidation burden, improved scientific understanding, support for lifecycle management, and overall improved method reliability [13,18]. These advantages collectively position MODR as an indispensable component of AQbD-based analytical method development.

6.4 Chromatographic Applications

MODR-based optimization has been successfully applied to HPLC, UPLC, and GC methods, where the multi-parameter nature of separation science makes the approach particularly valuable. MODR establishment in these settings has consistently translated into better peak resolution, shorter run times, and improved inter-laboratory reproducibility [13,16].

7. CONTROL STRATEGY IN AQBD

A rigorously designed control strategy is the operational embodiment of the knowledge generated during AQbD-based development. It comprises the ensemble of planned controls, monitoring mechanisms, and acceptance criteria that collectively ensure continuous compliance with ATP requirements throughout the method's working life. The conceptual basis for control strategy formulation is provided by ICH Q8(R2), Q9, Q10, and Q14, which collectively advocate risk-based, scientifically founded, and lifecycle-oriented analytical control [1–5].

Control strategy development is initiated after MODR establishment, building on the mechanistic understanding of CMPs and CQAs accumulated during risk assessment and DoE. Its implementation ensures that identified critical parameters remain within MODR boundaries during routine operations, suppressing variability and OOS occurrences [13,14].

7.1 Key Elements of the Control Strategy

Control of Critical Method Parameters

CMPs identified during development spanning mobile phase composition, eluent flow rate, column temperature, buffer pH, detection wavelength, injection volume, and sample preparation conditions must be actively monitored and maintained within MODR-defined limits throughout routine use [13,18].

System Suitability Testing

Prior to each analytical run, system suitability experiments verify that the instrument is operating within its qualified performance envelope. Assessed parameters typically include peak resolution, tailing factor, theoretical plate count, retention time reproducibility, and peak area precision. Both USP <621> and USP <1220> accord system suitability testing a prominent place within lifecycle-based method control [7,8].

Method Performance Monitoring

Ongoing tracking of accuracy, precision, robustness, repeatability, and intermediate precision constitutes the early-warning mechanism for performance drift. Performance trending, as recommended in USP <1220>, enables timely identification of emerging method issues before they manifest as OOS results [7].

Environmental Controls

Laboratory temperature, humidity, and ambient conditions can subtly but measurably affect analytical outcomes. Consistent environmental management is therefore an integral component of the overall control framework.

Instrument Qualification and Calibration

Regular qualification activities  encompassing Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ)  along with routine detector calibration, pump performance checks, and autosampler accuracy verification, ensure that the analytical platform remains fit for purpose [18].

Sample Preparation Controls

Standardized sample preparation protocols, validated extraction procedures, and structured analyst training programmes collectively mitigate one of the primary sources of within-laboratory variability.

7.2 Control Strategy and Lifecycle Management

The control strategy serves as the operational backbone of lifecycle management by institutionalizing continuous performance evaluation and providing the framework for method evolution. Consistent with ICH Q14 and USP <1220>, analytical methods should be subject to ongoing assessment, and performance data accumulated during routine analysis should feed back into control strategy refinement and method improvement. Lifecycle management encompasses continued performance verification, statistical trend analysis, periodic comprehensive review, and structured change management [5,7].

8. AQBD-BASED METHOD VALIDATION

AQbD-based method validation reconceives the validation function as a continuous, integrated process rather than a terminal event. Under this paradigm, validation activities are initiated during early development and progress in parallel with method optimization, resulting in a seamless transition from development to routine application. The regulatory basis for this integrated approach resides in ICH Q2(R2), Q8(R2), Q9, Q14, and USP <1220> [1,2,5,6,7].

A particular advantage of this approach is that validation work spans the MODR, rather than being limited to a single fixed operating point. This breadth of validation provides direct evidence of method robustness and supports the claim that performance is assured across the entire acceptable operating space [13,14,18].

8.1 Validation Parameter Framework

Accuracy

Closeness between measured and reference values is assessed through recovery experiments conducted at multiple concentration levels, typically spanning the range of anticipated sample concentrations.

Precision

Three tiers of precision repeatability within a single analytical session, intermediate precision across analysts and days, and reproducibility across sites characterize the method's vulnerability to random variation.

Specificity

The method's capacity to quantify the target analyte in the presence of potential interferences including excipients, synthetic impurities, and degradation products is confirmed, with particular emphasis on stability-indicating capability.

Linearity

The proportionality of analytical response to analyte concentration is established across the intended working range, with statistical characterization of the calibration function.

Detection and Quantitation Limits

The Limit of Detection (LOD) and Limit of Quantitation (LOQ) demarcate the lower operational boundary of the method, confirming its sensitivity for trace-level work.

Robustness via DoE

Robustness assessment within AQbD is executed through DoE rather than single-factor perturbation studies, providing a comprehensive map of how simultaneous minor variations in multiple parameters affect analytical performance [6,13,18].

8.2 MODR Validation

Performance is confirmed across the full MODR, providing documented assurance that the method operates reliably anywhere within the defined space. Parameters adjusted within MODR boundaries do not require revalidation, provided ATP criteria are continuously satisfied [5,18].

8.3 Ongoing Performance Management

The post-validation lifecycle phase encompasses system suitability testing, performance trending, periodic review, and structured change management, all anchored by the lifecycle management frameworks of USP <1220> and ICH Q14 [5,7].

9. Lifecycle Management of Analytical Methods

Lifecycle management is the mechanism through which AQbD's proactive, knowledge-based philosophy is sustained across the full operational history of an analytical method from its initial conception through development, validation, routine deployment, and eventual retirement. This contrasts with traditional approaches in which validation marks an endpoint rather than a milestone in an ongoing stewardship process. The lifecycle perspective is formally endorsed by ICH Q8(R2), Q9, Q10, Q14, Q2(R2), and USP <1220> [1–7].

Fig. 2 Analytical procedure life cycle

Stage 1: Analytical Method Development

The developmental stage is where the foundational knowledge supporting the method's entire lifecycle is generated. Key activities include ATP formulation, CQA and CMP identification, risk evaluation using Ishikawa diagrams and FMEA, DoE-based variable optimization, and MODR establishment. The scientific depth achieved here directly governs the method's downstream robustness and adaptability [13,14,18]. Risk assessment at this stage ensures that subsequent development effort is concentrated on the variables that most significantly influence method quality [2,16].

Stage 2: Method Validation and Performance Qualification

Formal validation activities confirm that the method satisfies its ATP requirements. AQbD-based validation is distinguished by its breadth extending across the MODR rather than being confined to a single operating condition and by its integration with early-phase development work. Validation parameters encompass accuracy, precision, specificity, linearity, LOD, LOQ, and robustness, in accordance with ICH Q2(R2) [5,6,7]. This stage also marks the establishment of the control strategy, incorporating system suitability testing, instrument qualification, analyst training, and performance monitoring protocols [18].

Stage 3: Continued Method Performance Verification

Throughout the routine operational life of the method, ongoing monitoring activities detect performance drift before it compromises results. These activities include trend analysis of system suitability results, retention time behaviour, peak resolution, analytical precision, and calibration consistency. Detected trends trigger structured change management processes that restore and improve method performance. This proactive approach is the practical expression of the lifecycle management principles articulated in USP <1220> and ICH Q14 [7,18].

10. APPLICATIONS OF AQBD IN PHARMACEUTICAL ANALYSIS

The reach of AQbD extends across virtually every subdiscipline of pharmaceutical analysis, wherever the need for robust, well-characterized, and lifecycle-compliant analytical methods is paramount. The systematic identification of ATPs, CQAs, and CMPs, coupled with MODR establishment, consistently delivers measurable gains in method reliability, analytical precision, and regulatory positioning [1–6].

10.1 Chromatographic Method Development

HPLC, UPLC, GC, and LC-MS methods have been the most extensively documented beneficiaries of AQbD. Parameters governing chromatographic performance including mobile phase composition, eluent flow, column temperature, pH, and detection wavelength are optimized using risk assessment and DoE, supporting applications in assay determination, impurity profiling, forced degradation studies, and dissolution testing [7–10].

10.2 Stability-Indicating Method Development

AQbD provides a principled basis for developing methods capable of distinguishing the parent drug from degradation products generated under stress conditions temperature, humidity, photolytic, oxidative, and hydrolytic stress ensuring the impurity separation, resolution, and regulatory compliance required by ICH Q1A guidelines [11,12].

10.3 Bioanalytical Method Development

In bioanalytical science, AQbD has been applied to LC-MS/MS, HPLC, and UPLC platforms to optimize sample preparation, extraction efficiency, and analytical conditions for plasma, tissue, and other biological matrices. The resulting improvements in sensitivity and reproducibility benefit pharmacokinetic, bioavailability, and therapeutic drug monitoring studies [13,14].

10.4 Dissolution Testing

AQbD-based optimization of dissolution media composition, pH, agitation speed, and temperature settings improves the reproducibility and discriminating power of dissolution tests, ensuring that release performance data are reliably informative [15].

10.5 Spectroscopic Methods

UV-Visible, FTIR, and NIR spectroscopic techniques benefit from AQbD-guided optimization of wavelength selection and instrumental parameters, enhancing measurement accuracy and reliability across diverse sample types [16].

10.6 Impurity Profiling

Systematic optimization of separation conditions using AQbD enhances the detection sensitivity and resolution of closely related impurities, supporting the safety-driven regulatory requirements governing pharmaceutical impurity control [17].

10.7 Herbal and Natural Product Analysis

The intrinsic chemical complexity and compositional variability of herbal materials are particularly amenable to structured AQbD-based management. Applications include chromatographic fingerprinting, quantification of marker compounds, and multi-component assays all yielding improved quality control outcomes for botanical medicines [18,19].

10.8 Process Analytical Technology (PAT)

AQbD provides the methodological framework for developing real-time analytical tools capable of supporting in-process monitoring and continuous manufacturing operations, advancing the pharmaceutical industry's transition toward real-time release testing [20].

11. ADVANTAGES OF AQBD

The AQbD framework confers a comprehensive array of practical benefits that collectively justify its adoption as the preferred approach to analytical method development in regulated pharmaceutical settings [1–5].

Improved Robustness

Systematic risk assessment and DoE together identify and manage critical variables, producing methods that maintain their performance characteristics under realistic operational fluctuations [6,7].

Deeper Method Understanding

AQbD builds a mechanistic model of how method parameters govern analytical outcomes, making troubleshooting more efficient and predictive, and enabling informed control strategy design [8].

Regulatory Flexibility

The MODR framework enables post-approval parameter adjustments within defined boundaries without regulatory reapproval, substantially reducing the administrative burden of post-development changes [1,9].

Development Efficiency

DoE-based multivariate optimization dramatically reduces the number of experiments required relative to OFAT approaches, compressing development timelines and reducing resource consumption [10].

Reduced Variability

The identification and control of variability sources through AQbD ensures consistent analytical performance across analysts, instruments, and laboratory sites [11].

Lifecycle Management Support

Continuous monitoring, systematic validation, and structured improvement processes embedded in the AQbD framework sustain method performance throughout the operational lifecycle [12].

Enhanced Transferability

Well-defined operating parameters and MODR boundaries facilitate reliable method transfer between development and quality control laboratories, reducing transfer failure rates [13].

Risk-Informed Decision Making

FMEA, Ishikawa diagrams, and RRF give development teams the analytical basis for prioritizing method development activities and making evidence-based decisions about method design [14].

Quality Assurance

Robust analytical methods produce more accurate measurements of assay, degradation products, and impurity levels, directly supporting product safety and patient outcomes [15].

Long-Term Cost Efficiency

Reduced method failures, minimized revalidation requirements, and avoidance of regulatory delays collectively make AQbD a cost-effective investment when viewed across the full product lifecycle [16].

12. CHALLENGES AND LIMITATIONS OF AQBD

Notwithstanding its substantial advantages, the practical implementation of AQbD is accompanied by genuine challenges spanning technical, human, and organizational dimensions [1–3].

Statistical Expertise Requirements

Proficiency in DoE, response surface methodology, and multivariate analysis is a prerequisite for effective AQbD implementation. Organizations lacking personnel with this competency face barriers to correct experimental design and rigorous data interpretation [4,5].

Extended Development Planning Phase

The structured planning activities that underpin AQbD encompassing ATP definition, risk assessment, and experimental design require more upfront time than conventional OFAT approaches, which can compress development timelines [6].

Software and Infrastructure Investment

AQbD relies on specialized statistical software packages such as Design-Expert®, Minitab®, and JMP®. The associated licensing and training costs represent a meaningful barrier, particularly for smaller organizations [7].

Data Management Complexity

Multivariate experimental programmes generate large, complex datasets. Adequate data handling, interpretation, and archiving infrastructure is required to extract, document, and maintain the knowledge generated [8].

Training and Capability Development

Effective AQbD adoption demands competency in risk assessment methodologies, statistical analysis, and lifecycle management practices areas that may require substantial capability-building investment before implementation can proceed [10].

Process Complexity

The multi-step nature of AQbD encompassing ATP definition, risk appraisal, DoE, MODR establishment, control strategy development, and lifecycle management  demands more careful process governance than traditional development workflows [11].

Software Dependency

The optimization and modelling components of AQbD are fundamentally software-dependent, requiring ongoing access to, and expertise in, licensed analytical and statistical platforms [12].

Limited Uptake in Resource-Constrained Settings

Academic laboratories and smaller pharmaceutical companies may struggle to marshal the resources, expertise, and infrastructure needed for full AQbD implementation [13].

Despite these obstacles, the long-term dividends of AQbD in method robustness, regulatory confidence, and analytical reliability provide compelling justification for investment in overcoming these challenges.

13. FUTURE PERSPECTIVES OF AQBD

The trajectory of AQbD points unmistakably toward broader adoption, greater technical sophistication, and deeper integration with emerging analytical and digital technologies. The convergence of automation, artificial intelligence, real-time analytics, and evolving regulatory expectations is poised to substantially amplify the impact and accessibility of AQbD [1–3].

Lifecycle-Integrated Method Governance

Future AQbD frameworks will increasingly embed lifecycle management as an integral rather than supplementary component, covering the seamless transition from development through transfer, validation, and long-term performance assurance minimizing revalidation burdens while maximizing method durability [4,5].

Automation and Digitalization

Laboratory automation and digital workflow management tools will curtail human-introduced variability, enhance reproducibility, and enable high-throughput experimental execution, making the AQbD development cycle faster and more accessible [6].

Artificial Intelligence and Machine Learning

AI and machine learning algorithms hold considerable promise for predictive method modelling, automated identification of critical parameters, and intelligent experimental design that reduces the total number of runs required to establish an MODR [7,8].

Process Analytical Technology Integration

The coupling of AQbD principles with PAT platforms will enable continuous in-process monitoring and real-time release testing, positioning analytical science as an active participant in continuous manufacturing operations [9].

Expanding Regulatory Acceptance

Regulatory bodies are progressively embedding AQbD expectations within guidance frameworks such as ICH Q8, Q9, Q10, and Q14. This trend will incentivize broader adoption and establish AQbD as a standard of care rather than a best practice [1,4].

Continuous Manufacturing Applications

AQbD will increasingly support continuous manufacturing environments through the development of real-time monitoring strategies and robust process control methods, enhancing both efficiency and product quality [10].

Advanced Analytical Platform Expansion

The AQbD paradigm will extend its reach to advanced techniques including LC-MS/MS, Raman spectroscopy, NIR spectroscopy, and capillary electrophoresis, broadening the scope of systematic method development [11].

Predictive Risk Modelling

Advanced multivariate risk assessment tools and predictive modelling approaches will refine the risk evaluation step, enabling more precise identification and management of critical factors [12].

Biopharmaceutical Analysis

The growing commercial importance of monoclonal antibodies, peptides, and vaccines will drive the adaptation of AQbD principles to the more complex analytical challenges posed by these modalities [13].

Broad Industry Penetration

Driven by regulatory expectations, quality improvements, and cost efficiency gains, AQbD adoption is expected to extend progressively across mid-size and smaller pharmaceutical enterprises [14].

14. AQBD FRAMEWORK: OVERALL WORKFLOW

The AQbD workflow is a structured, sequential process that transforms a clearly stated analytical need into a robust, validated, and lifecycle-managed method. Each step builds on the knowledge generated in the preceding one, ensuring that every design decision is scientifically grounded and purposefully aligned with the ATP [1–5].

Step 1: Define the ATP

Articulate the method's intended purpose and establish quantitative performance criteria spanning accuracy, precision, specificity, detection capability, and working concentration range. The ATP serves as both compass and benchmark throughout the development journey [6].

Step 2: Identify CQAs

Determine the measurable analytical characteristics  resolution, retention time, peak symmetry, sensitivity that are directly linked to method performance and must be controlled to satisfy ATP criteria [7].

Step 3: Conduct Risk Assessment

Deploy Ishikawa diagrams and FMEA to isolate CMPs including mobile phase composition, eluent flow rate, column temperature, and pH and rank their potential impact on method performance [8].

Fig. 3 AQBD Workflow

Step 4: Method Scouting

Conduct preliminary experiments to select suitable stationary phases, mobile phase systems, detection wavelengths, and sample preparation approaches prior to formal DoE execution [9].

Step 5: Apply DoE

Design and execute a statistically structured multivariate experiment to characterize variable interactions, build predictive models, and identify conditions that robustly satisfy ATP criteria [10].

Step 6: Establish the MODR

Analyse DoE model outputs to define the multidimensional parameter region within which all ATP performance criteria are simultaneously met. This region forms the operational envelope for the finalized method [11].

Step 7: Method Optimization

Select the optimal working point within the MODR, balancing resolution, sensitivity, run time, and practical operational considerations [12].

Step 8: Develop the Control Strategy

Formalize system suitability testing parameters and routine monitoring protocols that will maintain method performance within the MODR during routine use [13].

Step 9: Validate the Method

Formally confirm, in accordance with ICH Q2(R2), that the method meets its ATP requirements across all relevant validation dimensions, including accuracy, precision, specificity, and robustness [14].

Step 10: Implement Lifecycle Management

Establish performance trending, periodic review, and change management mechanisms that will sustain method reliability, support knowledge capture, and enable continuous improvement over the method's operational life [15].

15. RISK ASSESSMENT TOOLS IN AQBD

A structured portfolio of risk assessment instruments is available to practitioners undertaking AQbD-based method development. Each tool contributes a distinct analytical lens through which the sources and magnitude of analytical performance risk can be characterised, prioritized, and managed. ICH Q9 and Q14 both explicitly recommend structured risk evaluation as a prerequisite for systematic analytical method development [1–5].

The primary objectives of risk assessment are to surface critical analytical variables, evaluate their potential failure modes, rank their relative importance, guide the design of control measures, and ultimately improve method robustness across the lifecycle [6].

15.1 Common Risk Assessment Tools

Ishikawa (Fishbone) Diagram

The Ishikawa diagram maps the causal relationships between method parameters encompassing instrument settings, sample preparation procedures, and environmental factors and performance outcomes. Although its output is qualitative, it provides an invaluable structured overview of all plausible variability sources and serves as the entry point for more quantitative risk evaluation [7].

Failure Mode and Effects Analysis (FMEA)

FMEA assigns quantitative scores to each identified failure mode across three dimensions: severity of impact on method performance, likelihood of occurrence, and probability of detection before the failure reaches the end user. The product of these scores the Risk Priority Number (RPN)  ranks potential failures, guiding prioritization of experimental attention [8].

Risk Ranking and Filtering (RRF)

RRF arrays candidate variables according to their assessed contribution to method performance degradation, enabling rapid identification of the factors warranting detailed DoE investigation [9].

Pareto Analysis

Based on the 80/20 principle, Pareto analysis identifies the minority of variables responsible for the majority of analytical variability, focusing developmental resources where they will have the greatest impact [10].

Fault Tree Analysis (FTA)

FTA employs a deductive, top-down logic model to trace analytical failures back to their root causes, supporting both risk mitigation planning and post-incident investigation.

Hazard Analysis and Critical Control Points (HACCP)

Adapted from food safety applications, HACCP identifies specific procedural points within the analytical workflow where contamination, error, or process deviation could compromise method integrity, and defines control measures to address each hazard [11].

Cause-and-Effect Matrix

This tool quantitatively scores the relationship between each method variable and each analytical response, generating a numerical priority ranking that guides DoE factor selection.

Collectively, these tools improve method understanding, reduce variability, strengthen analytical robustness, support evidence-based regulatory submissions, and enhance the quality of decisions made throughout the AQbD development process [12].

16. DESIGN OF EXPERIMENTS: SUPPLEMENTARY CONSIDERATIONS

Beyond its primary role in MODR development, DoE contributes to AQbD at multiple stages of the analytical lifecycle, from early screening through post-approval change evaluation [1–4].

16.1 Key Components

Input Variables (Factors)

Factors represent the method parameters whose values are deliberately varied during the DoE most commonly mobile phase composition, eluent flow rate, buffer pH, column temperature, and detection wavelength. Their appropriate selection, informed by prior risk assessment, is critical to the validity and utility of the DoE [6].

Responses (Output Variables)

Responses are the measurable analytical outcomes  including resolution, retention time, peak symmetry, detection sensitivity, and analysis duration whose behaviour as a function of the factors is the central object of DoE investigation [7].

16.2 Design Types

Screening Designs

Full factorial, fractional factorial, and Plackett–Burman designs serve to identify, from a broad initial candidate set, the subset of factors that exert statistically significant effects on analytical performance.

Optimization Designs

Central Composite Design, Box–Behnken Design, and Response Surface Methodology allow the construction of high-resolution models of the response landscape in the neighbourhood of the optimum, facilitating precise MODR delineation [8,9].

16.3 Practical Applications

DoE is widely implemented across HPLC and UPLC method development, dissolution media optimization, spectroscopic wavelength selection, bioanalytical sample preparation, and the development of stability-indicating methods.

16.4 Software Platforms

Widely used statistical platforms for DoE implementation in AQbD settings include Design-Expert®, Minitab®, JMP®, and MODDE®, each offering tailored functionality for pharmaceutical experimental design and response surface analysis. These tools support the documentation and knowledge management demands of AQbD by providing structured output suitable for regulatory submission [10,11].

17. Comparison: Traditional vs. AQbD-Based Analytical Development

The introduction of AQbD has fundamentally altered how analytical method development is conceived and executed in regulated pharmaceutical settings. Where traditional approaches are reactive and empirically driven, AQbD is proactive, scientifically grounded, and lifecycle-aware. Regulatory bodies including ICH and the U.S. FDA encourage AQbD adoption in view of its demonstrably superior outcomes for method performance, regulatory positioning, and knowledge management [1–3, 4,5].

Table no. 1 comparison between Traditional vs. AQBD approach